Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
about
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancerBiologic and clinical significance of androgen receptor variants in castration resistant prostate cancerNSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesisCopy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaSpheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinomaSorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational statusBax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.Induction of cancerous stem cells during embryonic stem cell differentiation.Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugsTargeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.Decoding the androgen receptor splice variants.MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling.Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma.Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axisIncreasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study
P2860
Q26795625-FF435756-DFBE-4DC0-AA02-D59701062F5FQ26858922-C7D7A709-4D18-4635-8845-D0BFB511AA37Q27320669-52430EAD-6B0B-4D51-92B1-8F23D9D8E98DQ27853202-3BD9CCC0-9E33-4D46-8665-04420718F56DQ30585006-FD7C4F7D-6215-4629-9AC4-9DC46E1D18F6Q34586486-AC6213E0-B6FF-4D10-8658-7912D23E5E3CQ35603183-91F34B50-5658-4E0C-A086-BAB51FA98D53Q36268430-5B0B9710-85C3-43C8-9E09-3A65A3C48AA6Q36347664-81C6AEBD-47FA-41A9-8E4E-AB113E15782DQ36413738-4B4900A3-B726-45E5-B858-9B8B805F58E3Q36930091-247AF3D0-639A-4EF5-B08C-CB205AD0BFFCQ37040669-C0CC85F6-781E-4CDF-9A9F-12E5B38D0301Q37322621-89AF2A2A-1580-452A-9F16-B5B9AA9178B4Q38263870-A4DEBFA4-6B08-4DFB-813D-4661D123A601Q38782227-2017DC3B-22E9-4EFA-B8BC-9C46CF8888D1Q38802507-A09753DD-7A10-46CE-B0CC-0A5F0A939437Q38824756-7BC0CC19-33C1-4465-A7F6-B1262E2C8B86Q38940292-136DCE13-F80E-4B41-A05D-59884EC87200Q39037597-CF6BB257-FBA5-49F1-94D1-0819F5759834Q39251637-73D5AC5A-8045-437C-8DAA-8B5F888A68C0Q40880050-963DF4F4-F0C8-41EE-82D9-3DAF70D845F5Q41078957-ED42662A-95CF-40E8-883F-1582E9B90238Q42106395-3492708F-3ADE-47E0-BE51-ACAEC97A3991Q47161820-37F6B955-C619-49CC-BDCE-8E18A0F0C5E3Q47552580-A21C9FA0-D5C8-4299-B279-018703A281C3Q53156735-8EC92234-7ABC-4CC4-ACA0-208556B28B9FQ58544252-B9E2106B-A32D-4B9A-82B6-555FDC464A1D
P2860
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Sorafenib decreases proliferat ...... tor and Akt signaling pathways
@ast
Sorafenib decreases proliferat ...... tor and Akt signaling pathways
@en
type
label
Sorafenib decreases proliferat ...... tor and Akt signaling pathways
@ast
Sorafenib decreases proliferat ...... tor and Akt signaling pathways
@en
prefLabel
Sorafenib decreases proliferat ...... tor and Akt signaling pathways
@ast
Sorafenib decreases proliferat ...... tor and Akt signaling pathways
@en
P2093
P2860
P356
P1476
Sorafenib decreases proliferat ...... tor and Akt signaling pathways
@en
P2093
Alfred Hobisch
Frédéric R Santer
Holger H H Erb
Su Jung Oh
Zoran Culig
P2860
P304
P356
10.1530/ERC-11-0298
P577
2012-05-03T00:00:00Z